Neumora Therapeutics Inc (nasdaq:NMRA) Share Price

Company Profile

Business description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Contact
490 Arsenal Way
Suite 200
WatertownMA02472
USA
T: +1 857 760-0900
https://www.neumoratx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	20.50	-0.23%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,315.27	172.85	0.37%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	0.25	0.00%
NASDAQ	22,631.48	160.75	0.72%
Nikkei 225	45,045.81	257.62	-0.57%
NZX 50 Index	13,231.66	111.63	0.85%
S&P 500	6,664.36	32.40	0.49%
S&P/ASX 200	8,773.50	18.70	-0.21%
SSE Composite Index	3,820.09	11.57	-0.30%